Skip to main content
Erschienen in: Wiener klinische Wochenschrift 1/2014

01.04.2014 | original article

In vitro efficacy of curcumin on Trichomonas vaginalis

verfasst von: Benjamin Wachter, Michael Syrowatka, Andreas Obwaller, Julia Walochnik

Erschienen in: Wiener klinische Wochenschrift | Sonderheft 1/2014

Einloggen, um Zugang zu erhalten

Summary

Trichomonosis, the disease caused by the protozoan parasite Trichomonas vaginalis, is the most common curable sexually transmitted disease with 174 million cases per year worldwide. The emerging resistance against the current standard therapy with metronidazole is pushing the search for alternative drugs. The purpose of this study was to determine the efficacy of curcumin, a derivate of Curcuma longa, on T. vaginalis. The effective concentrations (ECs) were evaluated using three strains of T. vaginaliswith different metronidazole susceptibilities (ATCC 30001, ATCC 30236 and ATCC 50138) and dilution series of curcumin in 24-well microtitre assays. Curcumin was shown to be highly effective against T. vaginalis, and the susceptibility of the different strains was not affected by an existing resistance to metronidazole. After 24 h of incubation, the EC50 ranged from 73.0 to 105.8 µg/ml and the EC90 from 216.3 to 164.9 µg/ml. In all strains tested, a 100 % eradication of all trichomonal cells within 24 h was reached at a concentration of 400 µg/ml curcumin, the 50-fold concentration still being very well tolerated by human mucosa. Altogether, curcumin seems to be a promising candidate for topical treatment of trichomonosis.
Literatur
2.
Zurück zum Zitat Sutton M, Sternberg M, Koumans EH, et al. The prevalence of Trichomonas vaginalis infection among reproductive-age women in the United States, 2001–2004. Clin Infect Dis. 2007;45(10):1319–26.PubMedCrossRef Sutton M, Sternberg M, Koumans EH, et al. The prevalence of Trichomonas vaginalis infection among reproductive-age women in the United States, 2001–2004. Clin Infect Dis. 2007;45(10):1319–26.PubMedCrossRef
3.
Zurück zum Zitat Geelen TH, Hoebe CJ, Dirks A, et al. Low positivity rate after systematic screening for Trichomonas vaginalis in three patient cohorts from general practitioners, STI clinic and a national population-based chlamydia screening study. Sex Transm Infect. 2013;89(6):532–4.PubMedCrossRef Geelen TH, Hoebe CJ, Dirks A, et al. Low positivity rate after systematic screening for Trichomonas vaginalis in three patient cohorts from general practitioners, STI clinic and a national population-based chlamydia screening study. Sex Transm Infect. 2013;89(6):532–4.PubMedCrossRef
4.
Zurück zum Zitat Allsworth JE, Ratner JA, Peipert JF. Trichomoniasis and other sexually transmitted infections: results from the 2001–2004 National Health and Nutrition Examination Surveys. Sex Transm Dis. 2009;36(12):738–44.PubMedCentralPubMedCrossRef Allsworth JE, Ratner JA, Peipert JF. Trichomoniasis and other sexually transmitted infections: results from the 2001–2004 National Health and Nutrition Examination Surveys. Sex Transm Dis. 2009;36(12):738–44.PubMedCentralPubMedCrossRef
5.
Zurück zum Zitat Shew ML, Fortenberry JD, Tu W, et al. Association of condom use, sexual behaviors, and sexually transmitted infections with the duration of genital human papillomavirus infection among adolescent women. Arch Pediatr Adolesc Med. 2006;160(2):151–6.PubMedCrossRef Shew ML, Fortenberry JD, Tu W, et al. Association of condom use, sexual behaviors, and sexually transmitted infections with the duration of genital human papillomavirus infection among adolescent women. Arch Pediatr Adolesc Med. 2006;160(2):151–6.PubMedCrossRef
6.
Zurück zum Zitat Gottlieb SL, Douglas JM Jr, Foster M, et al. Incidence of herpes simplex virus type 2 infection in 5 sexually transmitted disease (STD) clinics and the effect of HIV/STD risk-reduction counseling. J Infect Dis. 2004;190(6):1059–67.PubMedCrossRef Gottlieb SL, Douglas JM Jr, Foster M, et al. Incidence of herpes simplex virus type 2 infection in 5 sexually transmitted disease (STD) clinics and the effect of HIV/STD risk-reduction counseling. J Infect Dis. 2004;190(6):1059–67.PubMedCrossRef
7.
Zurück zum Zitat McClelland RS, Sangare L, Hassan WM, et al. Infection with Trichomonas vaginalis increases the risk of HIV-1 acquisition. J Infect Dis. 2007;195(5):698–702.PubMedCrossRef McClelland RS, Sangare L, Hassan WM, et al. Infection with Trichomonas vaginalis increases the risk of HIV-1 acquisition. J Infect Dis. 2007;195(5):698–702.PubMedCrossRef
8.
Zurück zum Zitat Van Der Pol B, Kwok C, Pierre-Louis B, et al. Trichomonas vaginalis infection and human immunodeficiency virus acquisition in African women. J Infect Dis. 2008;197(4):548–54. Van Der Pol B, Kwok C, Pierre-Louis B, et al. Trichomonas vaginalis infection and human immunodeficiency virus acquisition in African women. J Infect Dis. 2008;197(4):548–54.
9.
10.
Zurück zum Zitat Schmid G, Narcisi E, Mosure D, et al. Prevalence of metronidazole-resistant Trichomonas vaginalis in a gynecology clinic. J Reprod Med. 2001;46(6):545–9.PubMed Schmid G, Narcisi E, Mosure D, et al. Prevalence of metronidazole-resistant Trichomonas vaginalis in a gynecology clinic. J Reprod Med. 2001;46(6):545–9.PubMed
11.
Zurück zum Zitat Petrin D, Delgaty K, Bhatt R, et al. Clinical and microbiological aspects of Trichomonas vaginalis. Clin Microbiol Rev. 1998;11(2):300–17.PubMedCentralPubMed Petrin D, Delgaty K, Bhatt R, et al. Clinical and microbiological aspects of Trichomonas vaginalis. Clin Microbiol Rev. 1998;11(2):300–17.PubMedCentralPubMed
12.
Zurück zum Zitat Hager WD. Treatment of metronidazole-resistant Trichomonas vaginalis with tinidazole: case reports of three patients. Sex Transm Dis. 2004;31(6):343–5.PubMedCrossRef Hager WD. Treatment of metronidazole-resistant Trichomonas vaginalis with tinidazole: case reports of three patients. Sex Transm Dis. 2004;31(6):343–5.PubMedCrossRef
13.
Zurück zum Zitat Kulda J. Trichomonads, hydrogenosomes and drug resistance. Int J Parasitol. 1999;29(2):199–212.PubMedCrossRef Kulda J. Trichomonads, hydrogenosomes and drug resistance. Int J Parasitol. 1999;29(2):199–212.PubMedCrossRef
14.
Zurück zum Zitat Sobel JD, Nagappan V, Nyirjesy P. Metronidazole-resistant vaginal trichomoniasis—an emerging problem. N Eng J Med. 1999;341(4):292–3.CrossRef Sobel JD, Nagappan V, Nyirjesy P. Metronidazole-resistant vaginal trichomoniasis—an emerging problem. N Eng J Med. 1999;341(4):292–3.CrossRef
15.
Zurück zum Zitat Narcisi EM, Secor WE. In vitro effect of tinidazole and furazolidone on metronidazole-resistant Trichomonas vaginalis. Antimicrob Agents Chemother. 1996;40(5):1121–5.PubMedCentralPubMed Narcisi EM, Secor WE. In vitro effect of tinidazole and furazolidone on metronidazole-resistant Trichomonas vaginalis. Antimicrob Agents Chemother. 1996;40(5):1121–5.PubMedCentralPubMed
16.
Zurück zum Zitat Kuriyama A, Jackson JL, Doi A, et al. Metronidazole-induced central nervous system toxicity: a systematic review. Clin Neuropharmacol. 2011;34(6):241–7.PubMedCrossRef Kuriyama A, Jackson JL, Doi A, et al. Metronidazole-induced central nervous system toxicity: a systematic review. Clin Neuropharmacol. 2011;34(6):241–7.PubMedCrossRef
17.
Zurück zum Zitat Chacko J, Pramod K, Sinha S, et al. Clinical, neuroimaging and pathological features of 5-nitroimidazole-induced encephalo-neuropathy in two patients: insights into possible pathogenesis. Neurol India. 2011;59(5):743–7.PubMedCrossRef Chacko J, Pramod K, Sinha S, et al. Clinical, neuroimaging and pathological features of 5-nitroimidazole-induced encephalo-neuropathy in two patients: insights into possible pathogenesis. Neurol India. 2011;59(5):743–7.PubMedCrossRef
18.
Zurück zum Zitat Connor TH, Stoeckel M, Evrard J, et al. The contribution of metronidazole and two metabolites to the mutagenic activity detected in urine of treated humans and mice. Cancer Res. 1977;37(2):629–33.PubMed Connor TH, Stoeckel M, Evrard J, et al. The contribution of metronidazole and two metabolites to the mutagenic activity detected in urine of treated humans and mice. Cancer Res. 1977;37(2):629–33.PubMed
19.
Zurück zum Zitat Lindmark DG, Muller M. Antitrichomonad action, mutagenicity, and reduction of metronidazole and other nitroimidazoles. Antimicrob Agents Chemother. 1976;10(3):476–82.PubMedCentralPubMedCrossRef Lindmark DG, Muller M. Antitrichomonad action, mutagenicity, and reduction of metronidazole and other nitroimidazoles. Antimicrob Agents Chemother. 1976;10(3):476–82.PubMedCentralPubMedCrossRef
20.
Zurück zum Zitat Koss CA, Baras DC, Lane SD, et al. Investigation of metronidazole use during pregnancy and adverse birth outcomes. Antimicrob Agents Chemother. 2012;56(9):4800–5.PubMedCentralPubMedCrossRef Koss CA, Baras DC, Lane SD, et al. Investigation of metronidazole use during pregnancy and adverse birth outcomes. Antimicrob Agents Chemother. 2012;56(9):4800–5.PubMedCentralPubMedCrossRef
21.
Zurück zum Zitat Kazy Z, Puho E, Czeizel AE. Teratogenic potential of vaginal metronidazole treatment during pregnancy. Eur J Obstet Gynecol Reprod Biol. 2005;123(2):174–8. Kazy Z, Puho E, Czeizel AE. Teratogenic potential of vaginal metronidazole treatment during pregnancy. Eur J Obstet Gynecol Reprod Biol. 2005;123(2):174–8.
22.
Zurück zum Zitat Centers for Disease Control and Prevention, Workowski KA, et al. Sexually transmitted diseases treatment guidelines, 2006. MMWR Recomm Rep. 2006;55(RR-11):1–94.PubMed Centers for Disease Control and Prevention, Workowski KA, et al. Sexually transmitted diseases treatment guidelines, 2006. MMWR Recomm Rep. 2006;55(RR-11):1–94.PubMed
23.
Zurück zum Zitat Blaha C, Duchene M, Aspock H, et al. In vitro activity of hexadecylphosphocholine (miltefosine) against metronidazole-resistant and -susceptible strains of Trichomonas vaginalis. J Antimicrob Chemother. 2006;57(2):273–8.PubMedCrossRef Blaha C, Duchene M, Aspock H, et al. In vitro activity of hexadecylphosphocholine (miltefosine) against metronidazole-resistant and -susceptible strains of Trichomonas vaginalis. J Antimicrob Chemother. 2006;57(2):273–8.PubMedCrossRef
24.
Zurück zum Zitat Kranzler M. Pentamycin—a new option for the treatment of infections with Trichomonas vaginalis? Diploma thesis, University of Vienna; 2011. eBook 978-3-656-14565-32011. Kranzler M. Pentamycin—a new option for the treatment of infections with Trichomonas vaginalis? Diploma thesis, University of Vienna; 2011. eBook 978-3-656-14565-32011.
25.
Zurück zum Zitat Sharma RA, Gescher AJ, Steward WP. Curcumin: the story so far. Eur J Cancer. 2005;41(13):1955–68.PubMedCrossRef Sharma RA, Gescher AJ, Steward WP. Curcumin: the story so far. Eur J Cancer. 2005;41(13):1955–68.PubMedCrossRef
26.
Zurück zum Zitat Buescher R, Yang L. Turmeric. In: Lauro GJ, Francis FJ, editors. Natural food colorants. New York: Marcel Dekker; 2000. Buescher R, Yang L. Turmeric. In: Lauro GJ, Francis FJ, editors. Natural food colorants. New York: Marcel Dekker; 2000.
27.
Zurück zum Zitat Perez-Arriaga L, Mendoza-Magana ML, Cortes-Zarate R, et al. Cytotoxic effect of curcumin on Giardia lamblia trophozoites. Acta Trop. 2006;98(2):152–61.PubMedCrossRef Perez-Arriaga L, Mendoza-Magana ML, Cortes-Zarate R, et al. Cytotoxic effect of curcumin on Giardia lamblia trophozoites. Acta Trop. 2006;98(2):152–61.PubMedCrossRef
28.
Zurück zum Zitat Khalafalla RE, Muller U, Shahiduzzaman M, et al. Effects of curcumin (diferuloylmethane) on Eimeria tenella sporozoites in vitro. Parasitol Res. 2011;108(4):879–86.PubMedCrossRef Khalafalla RE, Muller U, Shahiduzzaman M, et al. Effects of curcumin (diferuloylmethane) on Eimeria tenella sporozoites in vitro. Parasitol Res. 2011;108(4):879–86.PubMedCrossRef
29.
Zurück zum Zitat Mimche PN, Taramelli D, Vivas L. The plant-based immunomodulator curcumin as a potential candidate for the development of an adjunctive therapy for cerebral malaria. Malar J. 2011;10(Suppl. 1):S10.PubMedCentralPubMedCrossRef Mimche PN, Taramelli D, Vivas L. The plant-based immunomodulator curcumin as a potential candidate for the development of an adjunctive therapy for cerebral malaria. Malar J. 2011;10(Suppl. 1):S10.PubMedCentralPubMedCrossRef
30.
Zurück zum Zitat Shahiduzzaman M, Dyachenko V, Khalafalla RE, et al. Effects of curcumin on Cryptosporidium parvum in vitro. Parasitol Res. 2009;105(4):1155–61.PubMedCrossRef Shahiduzzaman M, Dyachenko V, Khalafalla RE, et al. Effects of curcumin on Cryptosporidium parvum in vitro. Parasitol Res. 2009;105(4):1155–61.PubMedCrossRef
31.
Zurück zum Zitat Koide T, Nose M, Ogihara Y, et al. Leishmanicidal effect of curcumin in vitro. Biol Pharm Bull. 2002;25(1):131–3.PubMedCrossRef Koide T, Nose M, Ogihara Y, et al. Leishmanicidal effect of curcumin in vitro. Biol Pharm Bull. 2002;25(1):131–3.PubMedCrossRef
32.
Zurück zum Zitat Changtam C, de Koning HP, Ibrahim H, et al. Curcuminoid analogs with potent activity against Trypanosoma and Leishmania species. Eur J Med Chem. 2010;45(3):941–56.PubMedCrossRef Changtam C, de Koning HP, Ibrahim H, et al. Curcuminoid analogs with potent activity against Trypanosoma and Leishmania species. Eur J Med Chem. 2010;45(3):941–56.PubMedCrossRef
33.
Zurück zum Zitat Allam G. Immunomodulatory effects of curcumin treatment on murine Schistosomiasis mansoni. Immunobiology. 2009;214(8):712–27.PubMedCrossRef Allam G. Immunomodulatory effects of curcumin treatment on murine Schistosomiasis mansoni. Immunobiology. 2009;214(8):712–27.PubMedCrossRef
34.
35.
Zurück zum Zitat Barthelemy S, Vergnes L, Moynier M, et al. Curcumin and curcumin derivatives inhibit Tat-mediated transactivation of type 1 human immunodeficiency virus long terminal repeat. Res Virol. 1998;149(1):43–52.PubMedCrossRef Barthelemy S, Vergnes L, Moynier M, et al. Curcumin and curcumin derivatives inhibit Tat-mediated transactivation of type 1 human immunodeficiency virus long terminal repeat. Res Virol. 1998;149(1):43–52.PubMedCrossRef
36.
Zurück zum Zitat Yadav VS, Mishra KP, Singh DP, et al. Immunomodulatory effects of curcumin. Immunopharmacol Immunotoxicol. 2005;27(3):485–97.PubMedCrossRef Yadav VS, Mishra KP, Singh DP, et al. Immunomodulatory effects of curcumin. Immunopharmacol Immunotoxicol. 2005;27(3):485–97.PubMedCrossRef
37.
Zurück zum Zitat Chainani-Wu N. Safety and anti-inflammatory activity of curcumin: a component of tumeric (Curcuma longa). J Altern Complement Med. 2003;9(1):161–8.PubMedCrossRef Chainani-Wu N. Safety and anti-inflammatory activity of curcumin: a component of tumeric (Curcuma longa). J Altern Complement Med. 2003;9(1):161–8.PubMedCrossRef
38.
Zurück zum Zitat Wei QY, Chen WF, Zhou B, et al. Inhibition of lipid peroxidation and protein oxidation in rat liver mitochondria by curcumin and its analogues. Biochim Biophys Acta. 2006;1760(1):70–7.PubMedCrossRef Wei QY, Chen WF, Zhou B, et al. Inhibition of lipid peroxidation and protein oxidation in rat liver mitochondria by curcumin and its analogues. Biochim Biophys Acta. 2006;1760(1):70–7.PubMedCrossRef
39.
Zurück zum Zitat Devasena T, Rajasekaran KN, Gunasekaran G, et al. Anticarcinogenic effect of bis-1,7-(2-hydroxyphenyl)-hepta-1,6-diene-3,5-dione a curcumin analog on DMH-induced colon cancer model. Pharmacol Res. 2003;47(2):133–40.PubMedCrossRef Devasena T, Rajasekaran KN, Gunasekaran G, et al. Anticarcinogenic effect of bis-1,7-(2-hydroxyphenyl)-hepta-1,6-diene-3,5-dione a curcumin analog on DMH-induced colon cancer model. Pharmacol Res. 2003;47(2):133–40.PubMedCrossRef
40.
Zurück zum Zitat Srivivasan A, Menon VP, Periaswamy V, et al. Protection of pancreatic beta-cell by the potential antioxidant bis-o-hydroxycinnamoyl methane, analogue of natural curcuminoid in experimental diabetes. J Pharm Pharm Sci. 2003;6(3):327–33.PubMed Srivivasan A, Menon VP, Periaswamy V, et al. Protection of pancreatic beta-cell by the potential antioxidant bis-o-hydroxycinnamoyl methane, analogue of natural curcuminoid in experimental diabetes. J Pharm Pharm Sci. 2003;6(3):327–33.PubMed
41.
42.
Zurück zum Zitat Fang HY, Chen SB, Guo DJ, et al. Proteomic identification of differentially expressed proteins in curcumin-treated MCF-7 cells. Phytomedicine. 2011;18(8–9):697–703.PubMedCrossRef Fang HY, Chen SB, Guo DJ, et al. Proteomic identification of differentially expressed proteins in curcumin-treated MCF-7 cells. Phytomedicine. 2011;18(8–9):697–703.PubMedCrossRef
43.
Zurück zum Zitat Wang L, Wang L, Song R, et al. Targeting sarcoplasmic/endoplasmic reticulum Ca2+-ATPase 2 by curcumin induces ER stress-associated apoptosis for treating human liposarcoma. Mol Cancer Ther. 2011;10(3):461–71.PubMedCrossRef Wang L, Wang L, Song R, et al. Targeting sarcoplasmic/endoplasmic reticulum Ca2+-ATPase 2 by curcumin induces ER stress-associated apoptosis for treating human liposarcoma. Mol Cancer Ther. 2011;10(3):461–71.PubMedCrossRef
44.
Zurück zum Zitat He ZY, Shi CB, Wen H, et al. Upregulation of p53 expression in patients with colorectal cancer by administration of curcumin. Cancer Investig. 2011;29(3):208–13.CrossRef He ZY, Shi CB, Wen H, et al. Upregulation of p53 expression in patients with colorectal cancer by administration of curcumin. Cancer Investig. 2011;29(3):208–13.CrossRef
45.
Zurück zum Zitat Elad S, Meidan I, Sellam G, et al. Topical curcumin for the prevention of oral mucositis in pediatric patients: case series. Altern Ther Health Med. 2013;19(3):21–4.PubMed Elad S, Meidan I, Sellam G, et al. Topical curcumin for the prevention of oral mucositis in pediatric patients: case series. Altern Ther Health Med. 2013;19(3):21–4.PubMed
46.
Zurück zum Zitat Manifar S, Obwaller A, Gharehgozloo A, et al. Curcumin gel in the treatment of minor aphthous ulcer: a randomized, placebo-controlled trial. J Med Plants. 2012;11(41):40–5. Manifar S, Obwaller A, Gharehgozloo A, et al. Curcumin gel in the treatment of minor aphthous ulcer: a randomized, placebo-controlled trial. J Med Plants. 2012;11(41):40–5.
47.
Zurück zum Zitat Heng MC. Wound healing in adult skin: aiming for perfect regeneration. Int J Dermatol. 2011;50(9):1058–66.PubMedCrossRef Heng MC. Wound healing in adult skin: aiming for perfect regeneration. Int J Dermatol. 2011;50(9):1058–66.PubMedCrossRef
48.
Zurück zum Zitat Helson L. Curcumin (diferuloylmethane) delivery methods: a review. Biofactors. 2013;39(1):21–6. Helson L. Curcumin (diferuloylmethane) delivery methods: a review. Biofactors. 2013;39(1):21–6.
49.
Zurück zum Zitat Patel MB, Mandal S, Rajesh KS. Formulation and kinetic modeling of curcumin loaded intranasal mucoadhesive microemulsion. J Pharm Bioallied Sci. 2012;4(Suppl. 1):S81–3.PubMedCentralPubMedCrossRef Patel MB, Mandal S, Rajesh KS. Formulation and kinetic modeling of curcumin loaded intranasal mucoadhesive microemulsion. J Pharm Bioallied Sci. 2012;4(Suppl. 1):S81–3.PubMedCentralPubMedCrossRef
50.
Zurück zum Zitat Berginc K, Skalko-Basnet N, Basnet P, et al. Development and evaluation of an in vitro vaginal model for assessment of drug’s biopharmaceutical properties: curcumin. AAPS PharmSciTech. 2012;13(4):1045–53.PubMedCentralPubMedCrossRef Berginc K, Skalko-Basnet N, Basnet P, et al. Development and evaluation of an in vitro vaginal model for assessment of drug’s biopharmaceutical properties: curcumin. AAPS PharmSciTech. 2012;13(4):1045–53.PubMedCentralPubMedCrossRef
51.
Zurück zum Zitat Di Pierro F, Rapacioli G, Di Maio EA, et al. Comparative evaluation of the pain-relieving properties of a lecithinized formulation of curcumin (Meriva()), nimesulide, and acetaminophen. J Pain Res. 2013;6:201–5.PubMed Di Pierro F, Rapacioli G, Di Maio EA, et al. Comparative evaluation of the pain-relieving properties of a lecithinized formulation of curcumin (Meriva()), nimesulide, and acetaminophen. J Pain Res. 2013;6:201–5.PubMed
52.
Zurück zum Zitat Kulac M, Aktas C, Tulubas F, et al. The effects of topical treatment with curcumin on burn wound healing in rats. J Mol Histol. 2013;44(1):83–90.PubMedCrossRef Kulac M, Aktas C, Tulubas F, et al. The effects of topical treatment with curcumin on burn wound healing in rats. J Mol Histol. 2013;44(1):83–90.PubMedCrossRef
Metadaten
Titel
In vitro efficacy of curcumin on Trichomonas vaginalis
verfasst von
Benjamin Wachter
Michael Syrowatka
Andreas Obwaller
Julia Walochnik
Publikationsdatum
01.04.2014
Verlag
Springer Vienna
Erschienen in
Wiener klinische Wochenschrift / Ausgabe Sonderheft 1/2014
Print ISSN: 0043-5325
Elektronische ISSN: 1613-7671
DOI
https://doi.org/10.1007/s00508-014-0522-8

Weitere Artikel der Sonderheft 1/2014

Wiener klinische Wochenschrift 1/2014 Zur Ausgabe

vorwort

Vorwort